The effect of L-Lysine on biomarkers involved in colorectal cancer

Intervention 1: L-Lisyne powder 1.5g twice per day in combination with drugs of chemical therapy for patients in treatment group. The duration of treatment with L-lysin is 3 month. Intervention 2: In control group : placebo is powder as the same shape and color as L-lysine in combination with chemotherapy drugs ,twice a day foe 3 month.;Treatment - Drugs;Treatment - Drugs;L-Lisyne powder 1.5g twice per day in combination with drugs of chemical therapy for patients in treatment group. The duration of treatment with L-lysin is 3 month.;In control group : placebo is powder as the same shape and color as L-lysine in combination with chemotherapy drugs ,twice a day foe 3 month. Primary outcome(s): ERCC1(Excision repair cross-complementing rodent repair deficiency, complementation group 1). Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;VEGF(Vascular endothelial growth facto). Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;DPD(Dihydropyrimidine dehydrogenase deficiency. Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;TS(Thymidylate synthase). Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit.;CEA-Carcino Embryonic Antigen. Timepoint: Baseline and 3 monhts following the end of treatment. Method of measurement: ELISA kit. Study Design: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention.